ARGX argenx SE
argenx SE (ARGX) trend channel, buy level and 3-month target on Trade The Path. Sector: Healthcare. Listed on NASDAQ. Levels below are fitted to this ticker's own swing highs and lows (Theil–Sen, log-price), then projected 3 months. If this ticker has no settled sample yet, treat the numbers as a geometric read, not a track record. Information only, not financial advice.
Broken out above, rising on both timeframes
Price has closed above the channel. The fitted trend may no longer describe this stock.
Read from the last 12 months of history we hold: rising, drifting +15% a year. Price is above both fitted ceilings, so there is no line overhead to break — and no fitted resistance to price the target against either. What would overturn this: a close below US$859.35 — the floor of the channel being read — after which the trend, not the entry, is what was wrong.
- 12 months read from
- US$859.65 – US$935.45 Rising channel, +15% a year
- Position in that channel
- 165% above the ceiling of it — 0% is the floor, 100% the ceiling
Price history, with the path projected 3 months forward
- Daily close
- Upper trend line (12 months)
- Lower trend line (12 months)
- Dashed after today: projected 3 months
- Our buy
- Our target
Our target
No published call today because price has closed 5.2% clear above the channel, so the fitted lines no longer describe where it is. No alerts are sent. The buy and target below are still this site's read of the fitted channel.
Buy at or below
US$859.76
level as at 17 Sept 2026
Our target
US$935.98
by 16 Dec 2026
Projected move
8.9%
gross, before costs
Price is at or through our target.
- Upper line touches
- 4
- Lower line touches
- 3
- Fit confidence
- 39%
- Fitted
- 16 Sept 2026
About argenx SE
argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span across key global markets, including the United States, Japan, Europe, the Middle East, Africa, and China. Its leading investigational therapy is efgartigimod, which is being developed to address a broad range of conditions. These include generalized myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary Sjögren's syndrome, post-COVID postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, ANCA-associated vasculitis, and antibody-mediated rejection. Also noted in connection with its lead product efforts is ENHANZE SC. The company's extensive development pipeline features several other promising candidates. Empasiprubart is in development for multifocal motor neuropathy, delayed graft function, and dermatomyositis. ARGX-119 is being investigated for congenital myasthenic syndrome and amyotrophic lateral sclerosis. Further pipeline assets include ARGX-213, which targets FcRn; ARGX-121 and ARGX-220, both designed to modulate the immune system; ARGX-109, which targets IL-6; and ARGX-118, developed for inflammatory indications. argenx is also advancing cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. The company’s portfolio encompasses several proprietary products and brands, such as VYVGART, VYVGART HYTRULO, VYVDURA, ARGENX, ABDEG, NHANCE, SIMPLE ANTIBODY, and ARGENXMEDHUB. Strategic collaborations are integral to argenx's business model. It maintains partnerships with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S, alongside numerous collaboration and license agreements with entities including Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. A specific collaboration with Genmab A/S focuses on the discovery, development, and commercialization of novel therapeutic antibodies for immunology and oncology applications. Additionally, argenx has a strategic collaboration with IQVIA Holdings Inc. for the provision of safety systems and related services.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Karen Massey
- Employees
- 1,863
- Country
- NL
Scorecard
Our own pillar scores, computed from the fundamentals below. They are not Morningstar ratings — that data is licensed and we do not redistribute it.
- Valuation
- —
- Profitability
- —
- Financial health
- —
- Cash generation
- —
Key statistics
- Market cap
- US$61.22B
- Enterprise value
- —
- Beta
- -0.02
- Avg volume
- 322.70K
- Revenue per share
- —
- Dividend yield
- —
- 52-week range
- 661.85-1072.75
- Exchange
- NASDAQ
Key ratios
- P/E (TTM)
- —
- PEG
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Current ratio
- —
- Quick ratio
- —
- Debt / equity
- —
- Interest cover
- —
Income statement
Balance sheet
Cash flow
Trend lines are fitted statistically to past swing highs and lows and projected forward on the assumption the same rhythm continues. It often does not. This is information, not advice.